Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1997-01-31
1999-03-30
Bawa, Raj
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424489, 514 3, 514 4, 514866, A61K 912, A61K 3828
Patent
active
058884777
ABSTRACT:
The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of monomeric insulin and/or an inhale-exhale breathing maneuver. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by the monomeric form of insulin and by instructing the patient to inhale maximally and thereafter exhale maximally. This maneuver causes a spike in the rate at which insulin enters the circulatory system thereby increasing the rate at which glucose is removed from the circulatory system. The insulin or insulin analog may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release. The sensor can also assist the patient in the inhale-exhale maneuver.
REFERENCES:
patent: 3812854 (1974-05-01), Michaels et al.
patent: 3991304 (1976-11-01), Hillsman
patent: 4106503 (1978-08-01), Rosenthal
patent: 4343798 (1982-08-01), Fawri
patent: 4361401 (1982-11-01), Smith et al.
patent: 4468464 (1984-08-01), Cohen et al.
patent: 4604847 (1986-08-01), Moulding, Jr. et al.
patent: 4624251 (1986-11-01), Miller
patent: 4627432 (1986-12-01), Newell et al.
patent: 4639435 (1987-01-01), Fujii et al.
patent: 4677975 (1987-07-01), Edgar et al.
patent: 4686231 (1987-08-01), Bender et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4755383 (1988-07-01), Fujii et al.
patent: 4819629 (1989-04-01), Jonson et al.
patent: 4877989 (1989-10-01), Drews et al.
patent: 4926852 (1990-05-01), Zoltan et al.
patent: 4984158 (1991-01-01), Hillsman
patent: 5006343 (1991-04-01), Benson et al.
patent: 5011678 (1991-04-01), Wang et al.
patent: 5167506 (1992-12-01), Kilis et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5284133 (1994-02-01), Burns et al.
patent: 5320094 (1994-06-01), Laube et al.
patent: 5333106 (1994-07-01), Lanpher et al.
patent: 5363842 (1994-11-01), Mishelevich et al.
patent: 5364838 (1994-11-01), Rubsamen
patent: 5394866 (1995-03-01), Ritson et al.
patent: 5404871 (1995-04-01), Goodman et al.
patent: 5437267 (1995-08-01), Weinstein et al.
patent: 5446020 (1995-08-01), Andy et al.
patent: 5450336 (1995-09-01), Rubsamen et al.
patent: 5497944 (1996-03-01), Weston et al.
patent: 5509404 (1996-04-01), Lloyd et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5522385 (1996-06-01), Lloyd et al.
patent: 5544646 (1996-08-01), Lloyd et al.
patent: 5547929 (1996-08-01), Anderson
patent: 5693608 (1997-12-01), Bechgaard et al.
patent: 5700662 (1997-12-01), Chance et al.
patent: 5743250 (1998-04-01), Gonda et al.
Barker et al., "Acidic Precursor Revealed in Human Eosinophil Granule Major Basic Protein cDNA," J. Exp. Med., 168:1493-1498 (1988).
Berger et al., "Guide to Molecular Cloning Techniques," Methods in Enzymology, 152:664-704 (1987).
Collins et al., "Continous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture," Nature, 270:347-349 (1977).
Colthorpe, P., et al., 1992, "The pharmacokinetics of pulmonary delivered insuln: a comparison of intratracheal and aerosol administration to the rabbit," Parmaceutical Research 9:764-8.
Drazin et al., "Fungicidal Properties of a Chymotrypsin-Like Cationic Protein from Human Neutrophils: Absorption to Candida parapsilosis," Infect. Immun., 382-388 (1977).
Elliott, R.B. et al., "Parenteral absorption of insulin from the lung in diabetic children," 1987, Aust. Paediatr. J. 23: 293-297.
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability-Increasing Neutrophil Protein and a Closely Associated Phospholipase A.sub.2 from Rabbit Polmorphonuclear Leukocytes," The Journal of Biological Chemistry, 254:11000-11009 (1979).
Elsbach et al., "Bactericidal/Permeability Increasing Protein (BPI) of Granulocytes: Structure and Function," Bacteria-Host Interaction, 47-60 (1988).
Farley et al., "Antimicrobial Binding of a Radiolabeled Cationic Neutrophil Granule Protein," Infection and Immunology, 55:1536-1539 (1987).
Gabay et al., "Antibiotic Proteins of Human Polymorphonuclear Leukocytes," Proc. Natl. Acad. Sci., USA 86:5610-5614 (1989).
Gabay et al., "Azurophil-derived Bactericidal Factor(s) from Human Neutrophils," Clinical Research, 34:676A 1986).
Gabay et al., "Subcellular Location and Properties of Bactericidal Factors from Human Neutrophils," J. Exp. Med., 186:1407-1421 (1986).
Ganz et al., "Defensins: Natural Peptide Antibiotics of Human Neutrophils," J. Clin. Invest., 76:1427-1435 1985).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," The Journal of Biological Chemistry, 264:9505-9509 (1989).
Gray et al. "Cloning of the Gene of the Human Bactericidal/Permeability Increasing Protein and Identification of Structure-Function Relationships," Clinical Research, 36:620A (1988).
Gubler et al., "A Simple and Very Efficient Method for Generating cDNA Libraries," Gene, 25:263-269 (1983).
Heck et al., Isolation, Characterization, and Amino-Terminal Amino Acid Sequence Analysis of Human Neutrophil Elastase from Normal Donors, Anal. Biochem., 149:153-162 (1985).
Heck., "Isoation, Characterization, and Amino-terminal Amico Acid Sequence Analysis of Human Neutrophil Cathepsin G from normal Donors," Anal. Biochem., 158:217-227 (1986).
Heron, "System for Automated DNA Synthesis," Am. Biotechnol. Lab., 2:52-54, 56, 58-59 (1984).
Hovde et al., "Physiological Effects of a Bactericidal Protein from Human Polymorphonuclear Leudocytes on Pseudomonas aeruginosa," Infect. Immun., 52:90-95 (1986).
Hovde et al., "Characterization of a Protein from Normal Human Polymorphonuclear Leukocytes with Bactericidal Activity against Pseudomonas aeruginosa," Infection and Immunity, 54:142-148 (1986).
Hunkapiller et al., "High-Sensitivity Sequencing with a Gas-Phase Sequenator," Meth. Enzymol., 91:399-413 (1983).
Klein, Immunology: The Science of Self-Nonself Discrimination. John Wiley & Sons, NY. p. 101.
Kohler, D., 1990, "Aerosols for systemic treatment," Lung, Suppl. :677-84.
Larrick et al., "Complementary DNA Sequence of Rabbit Cap 18--A Unique Lipopolysaccharide Binding Protein," Biochem. Biophys. Research Communications 179:170-175 (1991).
Lauber, B.L. et al., 1991, "Deposition, clearance, and effects in the lung," Journal Aeorsol Medicine 4:286.
Lauber, B.L. et al., "Preliminary Study of the Efficacy of insulin aerosol delivered by oral inhalation in diabetic patients," 1994, JAMA, 269:2106-2109.
Lehrer et al., Correlation of Binding of Rabbit Granulocyte Peptides to Candida albicans with Candidacidal Activity, Infect. Immun., 49:207-211 (1985).
Maniatis et al., (eds.) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. pp. 188-199 (1982).
Moses, A.C. et al., 1983, "Insulin administed intranasally as an insulin-bile salt aerosos-effectiveness and reproducibility in normal and diabetic subjects," Diabetes 32:1040-7.
Muello et al., "The Role of Endotoxin n the Action of the Bactericidal/Permeability Increasing Neutrophil Protein on the Bacterial Envelope," Clinical Research, 31:371A (1983).
Nachman et al., "Studies on Isolated Membranes of Azurophil and Specific Granules from Rabbit Polymorphonuclear Leukocytes," J. Cell Biol., 54:133-140 (1972).
Newman, S.P. et al., "Deposition of pressurized aerosols in the human respiratory tract," 1981, Thorax, 36:52-55.
Newman, S.P. et al., "How Should a pressurized .beta.-adrenergic bronchodilator be inhaled?" 1981, Eur. J. Respir. Dis. 62:3-21.
Newman, S.P. et al., "Deposition of pressurized suspension aerosols inhaled through extension devices," 1981, Am. Rev. Respir. Dis. 124:317-320.
Newman, S.P. et al., Deposition and Effects of In
Farr Stephen J.
Gonda Igor
Rubsamen Reid M.
Aradigm Corporation
Bawa Raj
Bozicevic Karl
LandOfFree
Use of monomeric insulin as a means for improving the bioavailab does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of monomeric insulin as a means for improving the bioavailab, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of monomeric insulin as a means for improving the bioavailab will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1211510